

Regarding the included study, Impulse Dynamics is providing this information for educational purposes only. Some or all the studied uses of the Optimizer described in the article have not been approved or cleared by the FDA.

INDICATIONS

The safety and performance of the OPTIMIZER Smart System is based on clinical investigations conducted with the prior generation devices, the OPTIMIZER IVs and III Systems, given the similarities between the Systems with regard to function, intended use, design characteristics, and the CCM™ signals. Summaries of these studies are available on Impulse Dynamics' website. (<http://www.impulse-dynamics.com/int/for-physicians/clinical-data/>)

The OPTIMIZER Smart System, which delivers CCM™ therapy, is indicated to improve 6-minute hall walk distance, quality of life and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for CRT, and have an LVEF ranging from 25% to 45%.

The OPTIMIZER Smart system delivers non-excitatory CCM™ signals to the heart and has no pacemaker or ICD functions.

CONTRAINDICATIONS AND PRECAUTIONS

Use of the OPTIMIZER Smart system is **contraindicated** in:

1. Patients with permanent or long-standing persistent atrial fibrillation or flutter
2. Patients with a mechanical tricuspid valve
3. Patients in whom vascular access for implantation of the leads cannot be obtained

WARNINGS

Potential Complications of Device Implantation

Just like any surgical procedure, implantation of an OPTIMIZER Smart IPG is associated with a certain risk. Complications of IPG implantation reported in the literature include but are not limited to: arrhythmias induced by the IPG, including life-threatening arrhythmias (e.g., ventricular fibrillation), infection, skin necrosis, device migration, hematoma formation, seroma and histotoxic reactions (also see: Potential Adverse Effects in the Appendix).

Programming high sensitivities (i.e., sensitivity settings less than 2 mV) may increase the system's susceptibility to electromagnetic interference, which could either inhibit or trigger signal delivery.

Acute and chronic complications reported in the literature include, but are not limited to: lead fracture, lead displacement, atrial or ventricular perforation, and rare cases of pericardial tamponade. Perforation of the ventricular wall can induce direct stimulation of the phrenic nerve or the diaphragm. An impedance change demonstrated on a check-up can be indicative of lead fracture, lead displacement, or perforation (also see: Potential Adverse Effects in the Appendix).

In very rare cases (<1%), transvenous lead placement can also lead to venous thrombosis and subsequent SVC syndrome.

Loss of sensing shortly after implant can be the result of lead displacement. In addition, loss of CCM™ signal delivery could be due to a lead fracture.

Atrial and Ventricular Arrhythmias Potentially Caused by Lead Implantation

As noted above, the use of transvenous leads may lead to arrhythmias, some of which may be life-threatening such as ventricular fibrillation and ventricular tachycardia. The use of screw-in leads such as those used for CCM™ signal delivery also have the potential of causing conduction disturbances such as bundle branch block. These can be minimized by performing the implant with the use of fluoroscopic guidance, ensuring that the leads are in appropriate position prior to fixation and by limiting the number of lead manipulations. Please read and follow all directions of the original Physician Manual for the leads that you intend to use to minimize adverse events connected to lead implantation.

Ventricular Arrhythmias Potentially Caused by CCM™ Signals

CCM™ signals are of greater strength than that of typical pacing pulses and are thus capable of eliciting activation of cardiac tissue when delivered outside of the absolute refractory period. CCM™ signals delivered outside of the ventricular absolute refractory period thus have the potential of causing signal-induced arrhythmias (some of which may be life-threatening, such as ventricular fibrillation and tachycardia). For this reason, it is imperative that CCM™ signal delivery parameters be chosen carefully. Most importantly, the various settings related to conditions that inhibit CCM™ signal delivery (e.g. Long AV Delay, Short AV Delay, LS Alert Window, refractory periods, and IEGM sensitivities) must be selected to allow delivery of CCM™ signals only on normally conducted (e.g. non-arrhythmic) beats, but inhibit them on beats of suspected ectopic or premature origin.

Regarding the included study, Impulse Dynamics is providing this information for educational purposes only. Some or all the studied uses of the Optimizer described in the article have not been approved or cleared by the FDA.

In addition, CCM™ signals may cause changes in the electrical conduction of tissue. For this reason, the delivery of CCM™ signals to the ventricular septum has the potential of causing bundle branch block that could lead to bradycardia. Through similar mechanisms, CCM™-induced changes in the electrical conduction of the myocardium have the potential of inducing tissue refractoriness that may facilitate the induction of reentrant tachyarrhythmias. It is recommended that the patient's rhythm be monitored carefully for changes in rhythm when CCM™ signals are delivered during lead implantation, as well as during first activation of the OPTIMIZER Smart IPG and subsequent follow-up visits. Changes in ventricular rhythm caused by the delivery of CCM™ signals may require relocating the leads, as well as reprogramming the CCM™ delay and amplitude to settings that do not cause changes in the patient's ventricular rhythm.

Atrial Arrhythmias Potentially Caused by CCM™ Signals

Atrial and supraventricular arrhythmias could theoretically be initiated when CCM™-induced ventricular activity is conducted retrograde to the atria, resulting in premature atrial depolarization. The OPTIMIZER Smart IPG may sense the ventricular activation resulting from the retrograde-induced atrial event and deliver CCM™ as programmed. In addition, strong CCM™ signals delivered through leads implanted in basal position close to the atria have the potential of directly stimulating the atria. If CCM™ delivery causes atrial activation through either of these mechanisms, and the atrial signal is then conducted to the ventricles, the cycle may develop into a condition similar to pacemaker-mediated tachycardia (PMT).

The main variables that may have an impact on CCM™ events leading to atrial activation are the location of lead placement on the right ventricular septum, CCM™ amplitude, and CCM™ delay. To prevent the occurrence of atrial arrhythmias due to CCM™ signal delivery, it is recommended that basal lead implant locations be avoided. The potential for direct atrial activation by CCM™ signals can be tested during the implant by delivering the strongest possible CCM™ signal 20 to 30 ms longer than the LS-CCM delay with which the IPG will be ultimately programmed, as long as this delay places the CCM™ signal, including its 40 ms balancing phase, completely within the ventricular absolute refractory period, and monitoring for atrial activations. In such a case, the delay should be programmed to a longer value and lack of atrial activation confirmed. Besides proper lead location and CCM™ parameter programming, the "Atrial Tachycardia Rate" must be programmed to a sufficiently low value as a protective measure against atrial arrhythmias that could be induced by CCM™ signal delivery.

APPENDIX

Potential Adverse Effects

Examples of adverse effects that may occur as the result of the surgical procedure are listed below in the order of their clinical severity:

1. Death
2. Arrhythmias (brady- or tachyarrhythmias including fibrillation)
3. Stroke or TIA ("transient ischemic attack")
4. Respiratory/ventilatory failure
5. RA/RV perforation
6. Hemorrhage
7. Infection
8. Pleura or pericardial effusion
9. Pneumothorax

Examples of additional adverse effects potentially occurring secondary to CCM™ signal delivery are listed in the table below in the order of their clinical severity:

1. Abnormal cardiac function
2. Atrial and Ventricular Tachyarrhythmias
3. Atrial and Ventricular Bradyarrhythmias
4. Worsening heart failure
5. Myocardial tissue damage
6. Chest pain

www.impulsedynamics.com

Important Notes:

1. **You can only share this in response to an unsolicited request** for the information contained in this document.**
2. **Please document the time and place of the unsolicited request that preceded your distribution of this document.**
3. **Do not bring up or imply that CCM® therapy results in improved peak VO2.**
4. **If unsure about any of this, please consult with your manager at Impulse Dynamics.**

**** An unsolicited request in this context means a customer has asked you for information contained in this article without you mentioning the subject and/or offering to share said information.**



Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure

Christian Butter, Sharad Rastogi, Hans-Heinrich Minden, Jürgen Meyhöfer, Daniel Burkhoff, and Hani N. Sabbah

J. Am. Coll. Cardiol. 2008;51;1784-1789

doi:10.1016/j.jacc.2008.01.036

This information is current as of May 7, 2008

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://content.onlinejacc.org/cgi/content/full/51/18/1784>



Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure

Christian Butter, MD,* Sharad Rastogi, MD,† Hans-Heinrich Minden, MD,* Jürgen Meyhöfer, MD,* Daniel Burkhoff, MD, PhD,‡ Hani N. Sabbah, PhD†

Bernau/Berlin, Germany; Detroit, Michigan; and New York, New York

- Objectives** The objective of this study was to test whether cardiac contractility modulation (CCM) electric signals induce reverse molecular remodeling in myocardium of patients with heart failure.
- Background** Heart failure is associated with up-regulation of myocardial fetal and stretch response genes and down-regulation of Ca^{2+} cycling genes. Treatment with CCM signals has been associated with improved symptoms and exercise tolerance in heart failure patients. We tested the impact of CCM signals on myocardial gene expression in 11 patients.
- Methods** Endomyocardial biopsies were obtained at baseline and 3 and 6 months thereafter. The CCM signals were delivered in random order of ON for 3 months and OFF for 3 months. Messenger ribonucleic acid expression was analyzed in the core lab by investigators blinded to treatment sequence. Expression of A- and B-type natriuretic peptides and α -myosin heavy chain (MHC), the sarcoplasmic reticulum genes SERCA-2a, phospholamban and ryanodine receptors, and the stretch response genes p38 mitogen activated protein kinase and p21 Ras were measured using reverse transcription-polymerase chain reaction and bands quantified in densitometric units.
- Results** The 3-month therapy OFF phase was associated with increased expression of A- and B-type natriuretic peptides, p38 mitogen activated protein kinase, and p21 Ras and decreased expression of α -MHC, SERCA-2a, phospholamban, and ryanodine receptors. In contrast, the 3-month ON therapy phase resulted in decreased expression of A- and B-type natriuretic peptides, p38 mitogen activated protein kinase and p21 Ras and increased expression of α -MHC, SERCA-2a, phospholamban, and ryanodine receptors.
- Conclusions** The CCM signal treatment reverses the cardiac maladaptive fetal gene program and normalizes expression of key sarcoplasmic reticulum Ca^{2+} cycling and stretch response genes. These changes may contribute to the clinical effects of CCM. (J Am Coll Cardiol 2008;51:1784-9) © 2008 by the American College of Cardiology Foundation

A large number of patients with advanced heart failure (HF) are refractory to optimal standard medical therapy. This has given rise to development and testing of a host of new device-based therapies (1). One recent and potentially broadly applicable treatment under investigation is cardiac contractility modulation (CCM) electrical signals (2,3). The CCM signals are relatively high-voltage electrical impulses applied to the myocardium during the absolute refractory period. These signals do not initiate a new contraction or

modify activation sequence as is the case with other therapies such as cardiac resynchronization therapy (4). Rather, CCM signals are intended to enhance systolic function of the failing myocardium (5-8). Preliminary clinical studies suggest that CCM signal therapy is safe and can also improve exercise tolerance and quality of life in patients with HF (3,9) without increasing myocardial oxygen consumption (10). Recent studies in experimental HF suggest that a novel mechanism underlying these effects is normalized expression of genes known to be pathologically up- or down-regulated in HF (8). The purpose of this study was to test whether similar effects are present in patients with HF.

From the *Heart Center Brandenburg in Bernau/Berlin, Bernau/Berlin, Germany; †Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michigan; and ‡Columbia University, New York, New York. Supported, in part, by research grants from Impulse Dynamics USA, Inc., and by the National Heart, Lung, and Blood Institute, #P01 HL074237-04. Dr. Burkhoff is an employee of Impulse Dynamics. Dr. Sabbah is a consultant to Impulse Dynamics.

Manuscript received October 12, 2007; revised manuscript received December 21, 2007, accepted January 15, 2008.

Methods

Patients and study protocol. The present study included data from 11 patients. This was a substudy of a random-

ized, double blind, multicenter, crossover study of CCM signal therapy in patients with ejection fraction <35% and New York Heart Association functional class II/III symptomatic HF despite optimal medical therapy conducted at 15 hospitals in Europe and included 164 patients (the FIX-CHF-4 [Fix-Chronic Heart Failure-4] study). The major exclusion criteria included atrial fibrillation, patient eligible for cardiac resynchronization therapy, peak $\text{VO}_2 < 10 \text{ ml/kg/min}$, hospitalization within 1 month for acute exacerbation of HF, revascularization within 1 month or acute myocardial infarction within 3 months of study entry.

Qualifying patients were implanted with an Optimizer System (Impulse Dynamics USA, Inc., Orangeburg, New York). Details of the system implant have been provided previously (10). Two weeks following implant, patients were randomized to 3 months of CCM signal treatment (group 1, ON, $n = 7$) or to sham treatment with the device left off (group 2, OFF, $n = 4$) (Fig. 1, phase I). Three months later, patients crossed over to the opposite treatment for an additional 3 months (phase II). Protocol-specified clinical follow-up visits at 3 and 6 months included cardiopulmonary stress test (peak VO_2), Minnesota Living with Heart Failure Questionnaire (MLHFQ) and 6-min walk test (6MW). Patients participating in the present substudy underwent right heart biopsies at baseline and at the end of the 3- and 6-month treatment periods. Samples were snap frozen, stored in liquid nitrogen, and sent to a core lab that was blinded to study sequence. Messenger ribonucleic acid (RNA) expression of glyceraldehyde-3-phosphate dehydrogenase, α -myosin heavy chain (MHC), A- and B-type natriuretic proteins, sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA-2a), phospholamban,

and ryanodine receptor (RyR2), sodium-calcium exchanger, and the stretch receptor genes p38 mitogen activated protein kinase and p21 Ras were measured. Details of the methods of isolation and analysis are identical to those reported previously (11,12). Band intensity of each gene was expressed as a percent of the intensity of the respective gene at baseline.

Data are expressed as mean \pm standard deviation. Data from this crossover study were analyzed according to the methods of Fleiss (13). In brief, after confirming the absence of a treatment-by-period interaction (by repeated measures analysis of variance), mean end-of-period values for ON and OFF periods are pooled and analyzed by paired t test. Correlations between clinical outcome data and changes in gene expression were performed by linear regression analysis.

The main study and the substudy were each approved by the local ethics committee. Written informed consent was obtained from all patients prior to entry.

Results

Clinical characteristics. Patient baseline characteristics are summarized in Table 1. All patients were Caucasian men with New York Heart Association functional class III symptoms despite treatment with beta-blockers, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers and, with one exception, spironolactone. Seven of

Abbreviations and Acronyms

- CCM** = cardiac contractility modulation
- DNA** = deoxyribonucleic acid
- HF** = heart failure
- MHC** = myosin heavy chain
- MLHFQ** = Minnesota Living with Heart Failure Questionnaire
- RNA** = ribonucleic acid
- SERCA-2a** = sarcoplasmic reticulum calcium adenosine triphosphatase
- 6MW** = 6-min walk test




Figure 1. FIX-CHF-4 Study Design

This was a prospective, randomized, double-blind, double crossover study. FIX-CHF-4 = Fix-Chronic Heart Failure-4.

Table 1. Baseline Clinical Characteristics

	Group 1	Group 2	Overall
n	7	4	11
Age (yrs)	63 \pm 10	63 \pm 10	63 \pm 9
% male	100	100	100
Idiopathic/ischemic	5/2	2/2	7/4
% NYHA functional class III	100	100	100
EF (%)	26 \pm 4	30 \pm 7	28 \pm 6
QRS (ms)	125 \pm 14	122 \pm 28	124 \pm 19
HR (beats/min)	70 \pm 10	80 \pm 18	74 \pm 13
SBP (mm Hg)	107 \pm 11	106 \pm 17	107 \pm 13
MLHFQ	43 \pm 20	28 \pm 14	37 \pm 19
6MW (m)	458 \pm 88	436 \pm 85	450 \pm 83
Peak VO_2 (ml O_2 /kg/min)	13.8 \pm 2.5	13.2 \pm 2.1	13.6 \pm 2.6
dP/dt _{max} (mm Hg/s)	860 \pm 94	921 \pm 134	881 \pm 108
Δ dP/dt _{max} (%)	13 \pm 4	12 \pm 5	13 \pm 4

dP/dt_{max} = peak positive rate of change of left ventricular pressure measured during Optimizer System implant; EF = ejection fraction; HR = heart rate; MLHFQ = Minnesota Living with Heart Failure Questionnaire; NYHA = New York Heart Association functional classification; QRS = QRS duration; SBP = systolic blood pressure; 6MW = 6-min walk test.

the patients were randomized to group 1 (CCM signal treatment during the first 3 months), and 4 patients were randomized to group 2 (placebo during the first 3 months). The groups were reasonably well-balanced with regard to other characteristics.

The MLHFQ scores averaged 23 ± 14 at the end of ON treatment periods compared with 35 ± 17 at the end of OFF treatment periods ($p = 0.08$). The 6MW averaged 453 ± 97 m at the end of ON treatment periods compared with 402 ± 111 m at the end of OFF treatment periods ($p = 0.27$). Finally, peak VO_2 averaged 14.5 ± 4.3 ml $\text{O}_2/\text{kg}/\text{min}$ at the end of ON treatment periods compared with 11.9 ± 3.8 ml $\text{O}_2/\text{kg}/\text{min}$ at the end of OFF treatment periods ($p = 0.15$). Because of the small number of patients and large standard deviations, none of these differences was statistically significant.

Gene expression. Typical Northern blots obtained from 1 group 1 and 1 group 2 patient are shown in Figure 2. The consistent intensity of the glyceraldehyde-3-phosphate dehydrogenase band signifies consistent messenger RNA loading between samples. Each panel shows the respective band at baseline, 3 months, and 6 months. Genes that are overexpressed in HF tended to decrease toward normal during CCM signal treatment, whereas genes that are underexpressed in HF tended to increase toward normal during CCM signal treatment. A detailed analysis of the α -MHC blots is shown in Figure 3. Band intensities were

normalized to their respective values obtained in the baseline heart failure state. Data from patients with ischemic and idiopathic cardiomyopathy are shown with dashed and solid lines, respectively. At the end of phase I, α -MHC expression increased in group 1 patients (device ON) (Fig. 3A) and stayed the same or decreased in group 2 patients (device OFF) (Fig. 3B). After crossover, expression decreased in group 1 patients when the device was switched off and increased in group 2 patients when the device was switched on. The overall comparisons are summarized in panel C where results from ON periods are pooled and results from OFF periods are pooled. As shown, there was a statistically significant $\sim 62.7 \pm 45.3\%$ increase in α -MHC expression above the HF baseline state in response to CCM signal treatment. As shown in this typical example, there was no substantive difference in the response identified in hearts with idiopathic and ischemic cardiomyopathies.

Results from the other genes examined are summarized in Figure 4. There were statistically significant changes during the ON periods in all genes examined compared to the baseline HF state. The SERCA-2a, phospholamban, and RyR2 (genes whose expression is decreased in chronic HF) all increased in response to 3 months of CCM signal treatment. A- and B-type natriuretic peptides, p38 mitogen activated protein kinase, p21 Ras, and sodium-calcium exchanger (genes whose expression is increased during




Figure 2 Representative Northern Blots

Representative Northern blots from 2 patients, 1 from each treatment group. Differences in band intensities between periods of active and sham treatment are evident. The GAPDH band intensities show consistency of ribonucleic acid loading of the various lanes. ANP = A-type natriuretic peptides; BL = baseline; BNP = B-type natriuretic peptides; CCM = cardiac contractility modulation; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; MHC = myosin heavy chain; PLB = phospholamban; p21 RAS = p21 Ras stretch receptor gene; p38MAPK = p38 mitogen activated protein kinase stretch receptor gene; RyR2 = ryanodine receptor; SERCA-2a = sarcoplasmic reticulum calcium adenosine triphosphatase.




Figure 3 α-MHC Gene Expression

Changes in α-myosin heavy chain (MHC) gene expression (quantified as percent of baseline) at the end of study periods in group 1 (A) and group 2 (B) patients. (C) Data summarized by pooling the end of ON periods from the 2 groups and end of OFF periods from the 2 groups. **Solid lines** show data from patients with idiopathic cardiomyopathy, whereas **dashed lines** are from patients with ischemic cardiomyopathy.

chronic HF) all decreased in response to 3 months of CCM signal treatment.

Clinical-molecular correlations. We explored correlations between changes in gene expression and clinical effects. Specifically, we correlated percent changes in expression of SERCA-2a and percent changes in peak VO_2 , MLHFS, and 6MW. These calculations were made by comparing 3-month data to baseline and also comparing 6- to 3-month data (Fig. 5). Despite the small number of patients, there were statistically significant correlations between changes in peak VO_2 and MLHFQ and the change in SERCA-2a expression. The correlation between SERCA-2a and 6MW

was not significant. These findings were similar for ischemic and idiopathic cardiomyopathy.

Discussion

We show that 3 months of CCM signal treatment is associated with improved expression of genes that are either abnormally down- or up-regulated in HF. No differences were identified in these responses in ischemic and idiopathic cardiomyopathies. Because no tissue samples were available from normal controls, all changes are reported relative to the baseline HF state. Therefore, it was not evaluated whether





Figure 4 Summary of Impact of CCM Signal Treatment on Gene Expression

Summary of impact of cardiac contractility modulation (CCM) signal treatment on expression of genes examined in this study. Data for each gene analyzed as summarized in text and in the legend of Figure 3. NCX = sodium-calcium exchanger; other abbreviations as in Figure 2.



gene expression was normalized by CCM signal treatment, just that it improved toward the normal state. These findings are complementary to recently reported (8) effects of chronic CCM signal treatment in experimentally induced HF in dogs. It is noteworthy that, as in the prior experimental study, the clinical and molecular effects are identified in patients already taking chronic beta-blocker therapy.

Early studies of the mechanisms underlying the acute effects of CCM signals focused on their impact on action potential (5), peak intracellular calcium (2,14), and calcium loading of the sarcoplasmic reticulum. The increase in calcium was assumed to be the mechanism of increased contractility. More recent studies have suggested that CCM signals can have an impact on gene expression and phos-

phorylation of key proteins (e.g., phospholamban) involved with calcium cycling and other basic aspects of cell function within hours of signal application (8,15). The results of the present study extend these prior findings by showing they are relevant to diseased human myocardium. These findings are interesting in light of prior basic research showing that low frequency, low intensity electromagnetic fields can induce gene expression and modify enzymatic reactions (such as protein phosphorylation) within minutes in in vitro systems (16). It has been suggested that electromagnetic fields accelerate electron transfer reactions that could in turn stimulate transcription by interacting with electrons in DNA to destabilize the hydrogen bonds holding the 2 DNA strands together.

However, rather than invoking a direct effect of CCM signal treatment on gene expression, it is also possible that the changes in gene expression are secondary to alleviation of mechanical stresses brought about by local and global changes in myocardial function. For example, decreases in A- and B-type natriuretic peptides, p21 Ras, and p38 mitogen activated protein kinase are typically interpreted as indicating reduced mechanical stresses. Thus, alleviating excessive myocardial stretch may be responsible for down-regulation of stretch response proteins and block an important signaling pathway for HF progression. Nevertheless, it must be acknowledged that the mechanisms of action and the link between changes in gene expression and clinical effects are not clarified.

Study limitations. The main limitation of the present study is the small number of patients, which is due to the invasive nature of the techniques required. Nevertheless, the correlations between changes in myocardial gene expression and functional status indexed by either MLWHFQ or peak VO_2 were of great interest. Although these findings are provocative, it would be premature to suggest any mechanistic link given the limited data available at this time. The present study was also limited to an evaluation of tissue sampled from the right ventricular septum in the region where CCM signals are applied, leaving open the question if the results would extend to the left ventricle. In the prior animal study (8), CCM-mediated changes in gene expression were present in the region of signal application for the first several hours and present globally within 3 months. Because left heart biopsy was not possible, we cannot confirm that the changes identified would also be present in the remote areas of the myocardium. Also, because of the relatively small amount of tissue available from an endomyocardial biopsy, analysis of protein content and function were not possible. In our prior animal study (17), where abundant amounts of tissue were available, messenger RNA expression, protein content, and protein function were all assessed.

Conclusions

Application of CCM signals to the failing heart for 3 months is associated with improved expression of genes

associated with excitation-contraction coupling, and decreased expression of genes is associated with myocardial stress. These findings are present in tissue from patients with HF of either ischemic or nonischemic etiology. Both of these findings are indicative of beneficial molecular reverse remodeling. These findings are complementary to recent findings of the impact of CCM signals on gene expression in experimental HF (8). These findings can be extended to failing human myocardium. However, the mechanisms by which CCM signal treatment has an impact on gene expression are not known. It is clear that if CCM signal treatment improves myocardial stress on local and global levels, secondary normalization of gene expression can occur. As discussed previously (17), however, direct (primary) effects cannot be excluded. A randomized clinical trial, currently underway in the U.S., is designed to definitively test the safety and efficacy of this form of novel electrical therapy for chronic advanced HF.

Acknowledgment

The authors are grateful to Ms. Jana Hoffman for her assistance with data collection.

Reprint requests and correspondence: Dr. Christian Butter, Heart Center Brandenburg Bernau/Berlin, Ladeburger Strasse 17, 16321 Bernau/Berlin, Germany. E-mail: c.butter@immanuel.de.

REFERENCES

1. Mancini D, Burkhoff D. Mechanical device-based methods of managing and treating heart failure. *Circulation* 2005;112:438–48.
2. Burkhoff D, Ben Haim SA. Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure. *Am J Physiol Heart Circ Physiol* 2005;288:H2550–6.
3. Lawo T, Borggreffe M, Butter C, et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. *J Am Coll Cardiol* 2005;46:2229–36.
4. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002;346:1845–53.
5. Brunckhorst CB, Shemer I, Mika Y, Ben Haim SA, Burkhoff D. Cardiac contractility modulation by non-excitatory currents: studies in isolated cardiac muscle. *Eur J Heart Fail* 2006;8:7–15.
6. Mohri S, He KL, Dickstein M, et al. Cardiac contractility modulation by electric currents applied during the refractory period. *Am J Physiol Heart Circ Physiol* 2002;282:H1642–7.
7. Pappone C, Rosanio S, Burkhoff D, et al. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2002;90:1307–13.
8. Imai M, Rastogi S, Gupta RC, et al. Therapy with cardiac contractility modulation electric signals improves left ventricular function and remodeling in dogs with chronic heart failure. *J Am Coll Cardiol* 2007;49:2120–8.
9. Pappone C, Augello G, Rosanio S, et al. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study. *J Cardiovasc Electrophysiol* 2004;15:418–27.
10. Butter C, Wellnhofer E, Schlegl M, Winbeck G, Fleck E, Sabbah HN. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. *J Card Fail* 2007;13:137–42.
11. Gupta RC, Mishra S, Yang XP, Sabbah HN. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. *Mol Cell Biochem* 2005;269:49–57.
12. Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. *Circulation* 1991;83:1866–72.
13. Fleiss JL. *The Design and Analyses of Clinical Experiments*. New York, NY: John Wiley and Sons, Inc., 1986.
14. Mohri S, Shimizu J, Mika Y, et al. Electric currents applied during the refractory period enhance contractility and systolic calcium in ferret. *Am J Physiol Heart Circ Physiol* 2002;284:H1119–23.
15. Mishra S, Gupta RC, Rastogi S, Haddad W, Mika Y, Sabbah HN. Short-term therapy with nonexcitatory cardiac contractility modulation electric signals increases phosphorylation of phospholamban in left ventricular myocardium of dogs with chronic heart failure (abstr). *Circulation* 2004;110:III604.
16. Blank M, Goodman R. Initial interactions in electromagnetic field-induced biosynthesis. *J Cell Physiol* 2004;199:359–63.
17. Imai M, Rastogi S, Gupta RC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. *J Am Coll Cardiol* 2007;49:2120–8.

Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure

Christian Butter, Sharad Rastogi, Hans-Heinrich Minden, Jürgen Meyhöfer, Daniel Burkhoff, and Hani N. Sabbah

J. Am. Coll. Cardiol. 2008;51;1784-1789

doi:10.1016/j.jacc.2008.01.036

This information is current as of May 7, 2008

Updated Information & Services	including high-resolution figures, can be found at: http://content.onlinejacc.org/cgi/content/full/51/18/1784
References	This article cites 16 articles, 6 of which you can access for free at: http://content.onlinejacc.org/cgi/content/full/51/18/1784#BIBL
Rights & Permissions	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://content.onlinejacc.org/misc/permissions.dtl
Reprints	Information about ordering reprints can be found online: http://content.onlinejacc.org/misc/reprints.dtl

